Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems

Experimental Biology and Medicine

Volumn 242, Issue 16, 2017, Pages 1605-1616

  Soto Gutierrez, Alejandro ^a   Gough, Albert ^a,b   Vernetti, Lawrence A ^a,b   Taylor, D L ^a,b,c   Monga, Satdarshan P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

hepatocytes; induced pluripotent stem cells; liver diseases; Liver zonation; microfluidics; microphysiology systems

Indexed keywords

ACYL COENZYME A DESATURASE; BETA CATENIN; GLUTAMATE AMMONIA LIGASE; HEPATOCYTE NUCLEAR FACTOR; LONG CHAIN FATTY ACID COENZYME A LIGASE; PHOSPHATIDYLCHOLINE; WNT PROTEIN;

CELL COMPARTMENTALIZATION; FATTY ACID METABOLISM; FATTY LIVER; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER LOBULE; MAPK SIGNALING; METABOLIC LIVER ZONATION; NONALCOHOLIC FATTY LIVER; ORGAN DISTRIBUTION; OXIDATIVE PHOSPHORYLATION; OXYGEN TENSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; STEATOSIS; VIRUS CARCINOGENESIS; VIRUS HEPATITIS; WNT SIGNALING; ANIMAL; CELL CULTURE; CYTOLOGY; HEPATITIS; INDUCED PLURIPOTENT STEM CELL; LIVER; LIVER TUMOR; METABOLISM; MICROFLUIDICS; MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RAT; VIROLOGY;

ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; FATTY LIVER; GENE EXPRESSION; HEPATITIS; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER; LIVER NEOPLASMS; MICE; MICROFLUIDICS; RATS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 85032359679     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370217707731     Document Type: Review

References (80)

1. Grompe M. The origin of hepatocytes. Gastroenterology 2005; 128: 2158–60.
2. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213: 286–300.
3. Bahar Halpern K, Shenhav R, Matcovitch-Natan O, Toth B, Lemze D, Golan M, Massasa EE, Baydatch S, Landen S, Moor AE, Brandis A, Giladi A, Stokar-Avihail A, David E, Amit I, Itzkovitz S. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature 2017; 542: 352–6.
4. Birchmeier W. Orchestrating Wnt signalling for metabolic liver zonation. Nat Cell Biol 2016; 18: 463–5.
5. Monga SP. beta-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 2015; 148: 1294–310.
6. Sekine S, Lan BY, Bedolli M, Feng S, Hebrok M. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 2006; 43: 817–25.
7. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006; 131: 1561–72.
8. Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S. Apc tumor suppressor gene is the “zonation-keeper” of mouse liver. Dev Cell 2006; 10: 759–70.
9. Braeuning A, Menzel M, Kleinschnitz EM, Harada N, Tamai Y, Kohle C, Buchmann A, Schwarz M. Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes. FEBS J 2007; 274: 4766–77.
10. Colletti M, Cicchini C, Conigliaro A, Santangelo L, Alonzi T, Pasquini E, Tripodi M, Amicone L. Convergence of Wnt signaling on the HNF4alpha-driven transcription in controlling liver zonation. Gastroenterology 2009; 137: 660–72.
11. Yang J, Mowry LE, Nejak-Bowen KN, Okabe H, Diegel CR, Lang RA, Williams BO, Monga SP. beta-catenin signaling in murine liver zonation and regeneration: a Wnt-Wnt situation!. Hepatology 2014; 60: 964–76.
12. Wang B, Zhao L, Fish M, Logan CY, Nusse R. Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver. Nature 2015; 524: 180–5.
13. Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, Kinzel B, Yang Y, Mao X, Nicholson TB, Zamponi R, Capodieci P, Valdez R, Rivera D, Loew A, Ukomadu C, Terracciano LM, Bouwmeester T, Cong F, Heim MH, Forbes SJ, Ruffner H, Tchorz JS. The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat Cell Biol 2016; 18: 467–79.
14. Barker N, Tan S, Clevers H. Lgr proteins in epithelial stem cell biology. Development 2013; 140: 2484–94.
15. Gougelet A, Torre C, Veber P, Sartor C, Bachelot L, Denechaud PD, Godard C, Moldes M, Burnol AF, Dubuquoy C, Terris B, Guillonneau F, Ye T, Schwarz M, Braeuning A, Perret C, Colnot S. T-cell factor 4 and beta-catenin chromatin occupancies pattern zonal liver metabolism in mice. Hepatology 2014; 59: 2344–57.
16. Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012; 18: 29–37.
17. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519–23.
18. Pacana T, Sanyal AJ. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep 2015; 7: 28–28.
19. Wattacheril J, Seeley EH, Angel P, Chen H, Bowen BP, Lanciault C, Caprioli RM, Abumrad N, Flynn CR. Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis. PloS One 2013; 8: e57165–e57165.
20. Beyoglu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol 2013; 59: 842–58.
21. Mantena SK, Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams GA, Doeller JE, Kraus DW, Darley-Usmar VM, Bailey SM. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009; 417: 183–93.
22. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016; 17: 774–774.
23. Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin Liver Dis 2009; 13: 621–30.
24. Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 564–8.
25. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714–9.
26. Schwen LO, Homeyer A, Schwier M, Dahmen U, Dirsch O, Schenk A, Kuepfer L, Preusser T, Schenk A. Zonated quantification of steatosis in an entire mouse liver. Comput Biol Med 2016; 73: 108–18.
27. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A, Network NCR. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008; 48: 829–34.
28. Liu H, Fergusson MM, Wu JJ, Rovira II, Liu J, Gavrilova O, Lu T, Bao J, Han D, Sack MN, Finkel T. Wnt signaling regulates hepatic metabolism. Sci Signal 2011; 4: ra6–ra6.
29. Gusdon AM, Song KX, Qu S. Nonalcoholic fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014; 2014: 637027–637027.
30. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147–52.
31. Edgerton DS, Ramnanan CJ, Grueter CA, Johnson KM, Lautz M, Neal DW, Williams PE, Cherrington AD. Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes 2009; 58: 2766–75.
32. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366(Pt 2): 377–91.
33. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008; 7: 125–34.
34. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, Stevens RD, Bain JR, Newgard CB, Farese RV, Sr Hevener AL, Farese RV, Jr. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007; 6: 69–78.
35. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45–56.
36. Keung W, Ussher JR, Jaswal JS, Raubenheimer M, Lam VH, Wagg CS, Lopaschuk GD. Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice. Diabetes 2013; 62: 711–20.
37. Conti R, Mannucci E, Pessotto P, Tassoni E, Carminati P, Giannessi F, Arduini A. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes 2011; 60: 644–51.
38. Behari J, Li H, Liu S, Stefanovic-Racic M, Alonso L, O'Donnell CP, Shiva S, Singamsetty S, Watanabe Y, Singh VP, Liu Q. beta-catenin links hepatic metabolic zonation with lipid metabolism and diet-induced obesity in mice. Am J Pathol 2014; 184: 3284–98.
39. Tian Y, Mok MT, Yang P, Cheng AS. Epigenetic activation of Wnt/beta-catenin signaling in NAFLD-associated hepatocarcinogenesis. Cancers (Basel) 2016; 8: 76–76.
40. Tian Y, Wong VW, Wong GL, Yang W, Sun H, Shen J, Tong JH, Go MY, Cheung YS, Lai PB, Zhou M, Xu G, Huang TH, Yu J, To KF, Cheng AS, Chan HL. Histone deacetylase HDAC8 promotes insulin resistance and beta-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res 2015; 75: 4803–16.
41. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47: 505–11.
42. Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, Monga SP. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant beta-catenin. Hepatology 2016; 64: 1587–605.
43. Mercer KE, Hennings L, Sharma N, Lai K, Cleves MA, Wynne RA, Badger TM, Ronis MJ. Alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis in male mice through activation of the Wnt/beta-catenin signaling pathway. Cancer Prev Res (Phila) 2014; 7: 675–85.
44. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118–27.
45. Chung RT, Baumert TF. Curing chronic hepatitis C – the arc of a medical triumph. N Engl J Med 2014; 370: 1576–8.
46. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553–62.
47. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2016; 176: 65–73.
48. Fang X, Zeisel MB, Wilpert J, Gissler B, Thimme R, Kreutz C, Maiwald T, Timmer J, Kern WV, Donauer J, Geyer M, Walz G, Depla E, von Weizsacker F, Blum HE, Baumert TF. Host cell responses induced by hepatitis C virus binding. Hepatology 2006; 43: 1326–36.
49. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15: 266–82.
50. Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ. Hepatitis C virus infection activates an innate pathway involving IKK-alpha in lipogenesis and viral assembly. Nat Med 2013; 19: 722–9.
51. Lerat H, Kammoun HL, Hainault I, Merour E, Higgs MR, Callens C, Lemon SM, Foufelle F, Pawlotsky JM. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem 2009; 284: 33466–74.
52. Moreau M, Riviere B, Vegna S, Aoun M, Gard C, Ramos J, Assenat E, Hibner U. Hepatitis C viral proteins perturb metabolic liver zonation. J Hepatol 2015; 62: 278–85.
53. Racine-Samson L, Scoazec JY, D'Errico A, Fiorentino M, Christa L, Moreau A, Roda C, Grigioni WF, Feldman G. The metabolic organization of the adult human liver: a comparative study of normal, fibrotic, and cirrhotic liver tissue. Hepatology 1996; 24: 104–13.
54. D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532–43.
55. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB, Finegold MJ, Grompe M. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature 2010 Oct 7; 467: 707–10.
56. Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 2002; 440: 345–52.
57. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009; 49: 821–31.
58. Lee JM, Yang J, Newell P, Singh S, Parwani A, Friedman SL, Nejak-Bowen KN, Monga SP. beta-catenin signaling in hepatocellular cancer: implications in inflammation, fibrosis, and proliferation. Cancer Lett 2014; 343: 90–7.
59. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334–41.
60. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Bottger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gomez-Lechon MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Haussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhutter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stober R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013; 87: 1315–530.
61. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. Toxicol Res (Camb) 2013; 2: 23–39.
62. Vernetti LA, Vogt A, Gough A, Taylor DL. Evolution of experimental models of the liver to predict human drug hepatotoxicity and efficacy. Clin Liver Dis 2017; 21: 197–214.
63. Saad B, Thomas H, Schawalder H, Waechter F, Maier P. Oxygen tension, insulin, and glucagon affect the preservation and induction of cytochrome P450 isoforms in cultured rat hepatocytes. Toxicol Appl Pharmacol 1994; 126: 372–9.
64. Ohno K, Maier P. Cultured rat hepatocytes adapt their cellular glycolytic activity and adenylate energy status to tissue oxygen tension: influences of extracellular matrix components, insulin and glucagon. J Cell Physiol 1994; 160: 358–66.
65. Maier P, Schawalder H. Physiological oxygen tension modulates the chemically induced mitogenic response of cultured rat hepatocytes. J Cell Physiol 1993; 156: 119–29.
66. Silva JM, O'Brien PJ. Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br J Cancer 1993; 68: 484–91.
67. Allen JW, Bhatia SN. Formation of steady-state oxygen gradients in vitro: application to liver zonation. Biotechnol Bioeng 2003; 82: 253–62.
68. Allen JW, Khetani SR, Bhatia SN. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci 2005; 84: 110–9.
69. Domansky K, Inman W, Serdy J, Dash A, Lim MH, Griffith LG. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010; 10: 51–8.
70. Sato A, Kadokura K, Uchida H, Tsukada K. An in vitro hepatic zonation model with a continuous oxygen gradient in a microdevice. Biochem Biophys Res Commun 2014; 453: 767–71.
71. McCarty WJ, Usta OB, Yarmush ML. A microfabricated platform for generating physiologically-relevant hepatocyte zonation. Sci Rep 2016; 6: 26868–26868.
72. Camp JP, Capitano AT. Induction of zone-like liver function gradients in HepG2 cells by varying culture medium height. Biotechnol Prog 2007; 23: 1485–91.
73. Bavli D, Prill S, Ezra E, Levy G, Cohen M, Vinken M, Vanfleteren J, Jaeger M, Nahmias Y. Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction. Proc Natl Acad Sci U S A 2016; 113: E2231–40.
74. Lee-Montiel F, George S, Gough A, Sharma A, Wu J, DeBiasio R, Zaidins D, Vernetti LA, Taylor DL. Control of oxygen tension recapitulates zone-specific functions in human liver microphysiology systems. Exp Biol Med. 2017;242:1617–32
75. Chandrasekera PC, Pippin JJ. Of rodents and men: species-specific glucose regulation and type 2 diabetes research. ALTEX 2014; 31: 157–76.
76. Kucera O, Cervinkova Z. Experimental models of non-alcoholic fatty liver disease in rats. World J Gastroenterol 2014; 20: 8364–76.
77. Gross C, Steiger K, Sayyed S, Heid I, Feuchtinger A, Walch A, Hess J, Unger K, Zitzelsberger H, Settles M, Schlitter AM, Dworniczak J, Altomonte J, Ebert O, Schwaiger M, Rummeny E, Steingotter A, Esposito I, Braren R. Model matters: differences in orthotopic rat hepatocellular carcinoma physiology determine therapy response to sorafenib. Clin Cancer Res 2015; 21: 4440–50.
78. Woodhead JL, Yang K, Siler SQ, Watkins PB, Brouwer KL, Barton HA, Howell BA. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol 2014; 5: 240–240.
79. Senutovitch N, Vernetti LA, Boltz R, DeBiasio R, Gough A, Taylor DL. Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med (Maywood) 2015; 240: 795–808.
80. Gough A, Vernetti LA, Bergenthal L, Shun TY, Taylor DL. The microphysiology systems database for analyzing and modeling compound interactions with human and animal organ models. Appl In Vitro Toxicol 2016; 2: 103–17.